PT - JOURNAL ARTICLE AU - Feeney, Megan P. AU - Bega, Danny AU - Kluger, Benzi M. AU - Stoessl, A. Jon AU - Evers, Christiana M. AU - De Leon, Rebeca AU - Beck, James C. TI - Weeding Through the Haze: A Survey on Cannabis Use Among People Living with Parkinson’s Disease in the US AID - 10.1101/2020.06.24.20139162 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.24.20139162 4099 - http://medrxiv.org/content/early/2020/06/26/2020.06.24.20139162.short 4100 - http://medrxiv.org/content/early/2020/06/26/2020.06.24.20139162.full AB - Symptomatic management of Parkinson’s disease (PD) is complex and many symptoms, especially non-motor symptoms, are not effectively addressed with current medications. In the US, cannabis has become more widely available for medical and recreational use, permitting those in the PD community to try alternative means of symptom control. However, little is known about the attitudes towards, and experiences with, cannabis use among those living with PD. To address this shortcoming, we distributed an anonymous survey to 7,607 people with PD in January 2020 and received 1,064 complete responses for analysis (14%). Respondents represented 49 states with a mean age of 71.2 years (± 8.3) and mean PD duration of 7.4 years (± 6.2). About a quarter of respondents (24.5%) reported cannabis use within the previous six months. Users reported learning about cannabis use from the internet/news (30.5%) and friends or other people with PD (26.0%). Cannabis users were more likely to report insufficient control of their non-motor symptoms with prescription medications than non-users (p < 0.005). Cannabis was primarily used for PD (63.6%) and was most often used to treat nonmotor symptoms of anxiety (45.5%), pain (44.0%) and sleep disorders (44.0%). However, nearly a quarter of users (23.0%) also reported they had stopped cannabis use in the previous six months, primarily due to a lack of symptom improvement (35.5%). Three quarters of respondents (75.5%) did not use cannabis, primarily because there was a lack of scientific evidence supporting efficacy (59.9%). Our results suggest that the lack of formal guidance or research evidence about cannabis for PD may in part underlie inconsistencies in both use and reported effectiveness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Western Institutional Review Board (WIRB) approved this study. Given the low-risk nature of the protocol and anonymous data collection, the Board found that this research meets the requirements for a waiver of consent under 45 CFR 46 116 (f) [2018 Requirements] 45 CRF 46.116(d) [Pre-2018 Requirements].All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.